$ABMD News
Last published 10mo ago
- 10mo agoABMDAbiomed, Inc. - Appeal, ReversedUS Patent Trial and Appeal Board
- 3y agoSTIMABMDDr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis MedicalGlobeNewswireRenowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech
- 3y agoABMDImpella Real-World Surveillance of Patients Using Sodium Bicarbonate - NCT05820451ClinicalTrials.govPrimary Endpoint Left Sided Impella, Primary Endpoint Right Sided Impella
- 3y agoABMDWhite Swell Medical Ltd. vs Abiomed, Inc. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 3y agoABMDWhite Swell Medical Ltd. vs Abiomed, Inc. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 3y agoABMDWhite Swell Medical Ltd. vs Abiomed, Inc. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 3y agoABMDWhite Swell Medical Ltd. vs Abiomed, Inc. - AIA Trial, Final Written DecisionUS Patent Trial and Appeal Board
- 3y agoABMDAwake Axillary Impella 5.5 Placement - A Feasibility Trial - NCT05782491ClinicalTrials.govSuccess of Using Regional Anesthesia for Impella 5.5 Placement, Time to participation in physical therapy, Time to destination therapy, (and 3 more...)
- 3y agoABMDIMPACT EU Post-Market Clinical Follow-Up Study - NCT05756751ClinicalTrials.govthe rate of post-cardiotomy cardiac failure, All-cause mortality and Safety Endpoint: Stroke (as defined by STS), Stroke (as defined by STS), (and 10 more...)
- 3y agoABMDWhite Swell Medical Ltd. vs Abiomed, Inc. - AIA Trial, Final DecisionUS Patent Trial and Appeal Board
- 3y agoABMDFDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical TrialBusiness WireAbiomed (NASDAQ:ABMD) announces the United States Food and Drug Administration (FDA) has approved the version of Impella ECP that will be used in the Impella ECP Pivotal Trial, and the first two patients have been
- 3y agoABMDJNJSMCISPGI+1Steel Dynamics Set to Join S&P 500; Super Micro Computer to Join S&P MidCap 400PR NewswireNEW YORK, Dec. 19, 2022 /PRNewswire/ -- S&P MidCap 400 constituent Steel Dynamics Inc. (NASD:STLD) will replace Abiomed Inc. (NASD:ABMD) in the S&P 500 and Super Micro Computer Inc. (NASD:SMCI) will replace Steel
- 3y agoABMDJNJJohnson & Johnson Announces Extension of Abiomed Tender Offer to December 21, 2022Business WireJohnson & Johnson (NYSE:JNJ), the world's largest, most diversified healthcare products company, today announced that Athos Merger Sub, Inc. ("Offeror"), a wholly owned subsidiary of Johnson & Johnson, has
- 3y agoABMDFDA Roundup: December 6, 2022FDA Press ReleasesToday, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a final guidance, Homeopathic Drug Products, describing the agency’s approach to prioritizing enforcement and regulatory actions for homeopathic products marketed in the U.S. without the required FDA approval. The FDA has developed a risk-based approach under which ...
- 3y agoABMDFirst Patients in the World Treated with Impella RP Flex with SmartAssistBusiness WireAbiomed (NASDAQ:ABMD) announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist, Abiomed's newest heart pump for patients experiencing right heart failure. All three
- 4y agoABMDAZTAXGNAzenta Announces Nomination of Tina S. Nova, Ph.D. and Dorothy E. Puhy to Board of DirectorsPR NewswireCHELMSFORD, Mass., Nov. 14, 2022 /PRNewswire/ -- Azenta, Inc. (NASDAQ:AZTA) today announced that Tina S. Nova, Ph.D. and Dorothy E. Puhy have been nominated for election to its Board of Directors at the Company's
- 4y agoITDECKJNJABMD+23Stocks making the biggest moves midday: Uber, Abiomed, Peloton, Carvana, Molson Coors and moreCNBCThese are the stocks posting the largest moves in midday trading Tuesday, Nov. 1.
- 4y agoABMDJNJAbiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over YearBusiness WireABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended September 30, 2022. Second Quarter 2023 Financial
- 4y agoABMDJNJJohnson & Johnson to Acquire AbiomedBusiness WireStrengthens Johnson & Johnson's MedTech Business with the Addition of Abiomed, a World-Leader in Heart Recovery Transaction to Bring Lifesaving Innovations to More Patients with Unmet Need Expected to Enhance
- 4y agoABMDImpella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart FailureBusiness WireAbiomed (NASDAQ:ABMD) announces that Impella RP Flex with SmartAssist has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA), the FDA's highest level of approval, as safe and effective to treat
- 4y agoABMDAbiomed Creates Patient Assistance Program to Address Disparities in HealthcareBusiness WireAnalysis of randomized controlled trial data shows non-Caucasian high-risk PCI patients significantly benefit from Impella-support Abiomed (NASDAQ:ABMD) announces a new program to address healthcare disparities in
- 4y agoABMDMedTechVets Appoints Patrice Sutherland, Enterprise Executive Director at Integra LifeScience, as New Board ChairpersonBusiness WireSucceeds Derek Herrera after two-year term Patrice Sutherland, enterprise executive director at Integra Life Sciences, has been appointed Chairperson of the Board of Directors for MedTechVets, a nonprofit organization
- 4y agoABMDAbiomed Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart FailureBusiness WireAbiomed (NASDAQ:ABMD) announces the U.S. Food and Drug Administration (FDA) has accepted and closed the post-approval study reports related to the pre-market approvals (PMA) for Impella heart pumps. The FDA's action is
- 4y agoABMDU.S. FDA Grants 510(k) Clearance for Impella Low Profile SheathBusiness WireSmaller Sheath Simplifies Access and Improves Ease-of-Use The United States Food and Drug Administration (FDA) has granted 510(k) clearance to Abiomed (NASDAQ:ABMD) for its Impella Low Profile Sheath. Compared to the
- 4y agoABMDYale University Study Demonstrates Significant Survival Benefit in High-Risk PCI with Impella SupportBusiness WireAn analysis of more than 2,000 patients from a large U.S. real-world database finds that patients who underwent a non-emergent high-risk PCI with the Impella heart pump (n=1,447) had significantly improved survival,
- 4y agoABMDAbiomed Second Quarter Fiscal 2023 Earnings and Conference Call NotificationBusiness WireAbiomed, Inc. (NASDAQ:ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the
- 4y agoABMDMulti-Center, Multi-Society Study of Impella-supported Patients with Cardiogenic Shock due to Myocarditis in Japan Achieves 30-day Survival of 77%Business WireAbiomed (ABMD) announces the result of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan shows a 30-day survival rate of 77% for patients with cardiogenic shock due to myocarditis. This study is an
- 4y agoABMDLarge, Multi-Center, Multi-Society Study of Impella-supported Patients Finds 30-day AMI Cardiogenic Shock Survival of 81%Business WireResults of a three-year, investigator-led study of all Impella-supported patients treated at 109 hospitals in Japan (n=1,344) show 30-day survival rates of 81% for AMI cardiogenic shock (AMICS) patients. The study is an update to a 2020 interim analysis
- 4y agoABMDUnloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI PatientsBusiness WireResults of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who received left ventricular (LV) unloading with Impella CP for 30
- 4y agoABMDFDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)Business WireFDA Also Approves and Closes RECOVER III Post-Approval Study Abiomed (NASDAQ:ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardi
- 4y agoABMDTCT 2022: Impella Enables Complete Revascularization, Improved Quality of Life and Native Heart RecoveryBusiness WireAbiomed (NASDAQ:ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022
- 4y agoABMDThe RECOVER IV Trial - NCT05506449ClinicalTrials.govAll-Cause Mortality, Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Days Alive Out-of-Hospital, Mean Change in Health-Related Quality of Life, as measured by Kansas City Cardiomyopathy Questionnaire
- 4y agoABMDRestore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by ImpellaBusiness WireConsistent evidence supports benefits of complete revascularization on LVEF, heart failure symptoms Abiomed (NASDAQ:ABMD) announces the results of the Restore EF study demonstrate Impella-supported high-risk percutaneous coronary intervention (PCI) l
- 4y agoABMDABIOMED Announces First Quarter Record Revenue of $277 Million, up 10% Year Over Year, up 12% in Constant Currency*Business WireABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announces financial results for the quarter ended June 30, 2022. First Quarter 2023 Financial Highlights: Revenue of $277 million, an increa
- 4y agoABMDBreethe Abiomed Recovery regisTry (BART) - NCT05473130ClinicalTrials.govSurvival up to the hospital discharge
- 4y agoABMDThe PROTECT-EU Study - NCT05466552ClinicalTrials.govDeath, Cerebrovascular accident, infarction, (and 5 more...)
- 4y agoABMDAbiomed First Quarter Fiscal 2023 Earnings and Conference Call NotificationBusiness WireAbiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, August 4, 2022, the Company will release financial results for the first quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Thursday, August 4, 2022
- 4y agoABMDAbiomed to Host Investor Call on Heart Failure Opportunity With Impella 5.5 and Impella BTR Heart PumpsBusiness WireAbiomed, Inc. (NASDAQ:ABMD) today announced that it will host an investor call on the heart failure opportunity with the Impella 5.5 and future Impella BTR heart pumps on June 24, 2022 from 2:30 p.m. – 3:30 p.m. ET. The event will include presentation
- 4y agoABMDAbiomed to Present (Live) at the William Blair 42nd Annual Growth Stock ConferenceBusiness WireAbiomed, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present (live) at the William Blair 42nd Annual Growth Stoc
- 4y agoABMDSCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock OutcomesBusiness WireAbiomed (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, will feature the most recent Impella research and technological advances aimed at improving outcomes for acute myocardial infarction cardiogenic shock (AMICS) p
- 4y agoABMDAbiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over YearBusiness WireFY 2022 Annual Revenue of $1.032 billion, Up 22% Versus Prior Year ABIOMED, Inc. (NASDAQ:ABMD), a leader in breakthrough heart, lung and kidney support technologies, today announced financial results for the quarter and fiscal year ended March 31, 20
- 4y agoABMDWorld's First Patient Implanted with Impella BTR Minimally Invasive Heart PumpBusiness WireAbiomed (NASDAQ:ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump's U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS). The first implant was
- 4y agoABMDImpella ECP Study (ECP Study) - NCT05334784ClinicalTrials.govRate of MACCE, Impella ECP-related major vascular complications (Safety Endpoint 1), Impella ECP-related Major Bleeding (Safety Endpoint 2), (and 4 more...)
- 4y agoABMDAbiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call NotificationBusiness WireAbiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, April 28, 2022
- 4y agoABMDFirst Patient in Japan Treated with Impella 5.5 with SmartAssistBusiness Wire5,000 Patients Treated Globally The versatility and innovation of Abiomed's (NASDAQ:ABMD) Impella 5.5 with SmartAssist, a minimally-invasive forward flow heart pump, is leading to continued adoption of the game-changing technology by surgeons around
- 4y agoABMDUse of the Impella BTR™ in Patients With Heart Failure: An Early Feasibility Study - NCT05291884ClinicalTrials.govFeasibility: successful hemodynamic support, Safety: Major Device-Related Adverse Events, Number of participants with Major Hemolysis, (and 6 more...)
- 4y agoABMDAbiomed to Host Investor Call on Impella ECP, the World's Smallest Heart Pump at 9 FrenchBusiness WireAbiomed, Inc. (NASDAQ:ABMD) today announced that it will host an investor call on Impella ECP on March 29, 2022 from 4:00 p.m. – 5:00 p.m. EDT. The event will include presentations from circulatory support leader, Dr. Amir Kaki, interventional cardiol
- 4y agoABMDAbiomed to Present at the SVB Leerink 11th Annual Global Healthcare ConferenceBusiness WireAbiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will hold a fireside chat at the SVB Leerink 11th Annual Global Healthc
- 4y agoABMDAbiomed Announces Record Revenue of $261 Million, up 13% Year Over YearBusiness WireIncreasing Low End of Guidance: $1,025 Million - $1,030 Million, up 21% - 22% ABIOMED, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, today announced financial results for the quarter ended December 31, 2021. Q3
- 4y agoABMDAbiomed Third Quarter Fiscal 2022 Earnings and Conference Call NotificationBusiness WireAbiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022. The Company will host a conference call to discuss the results on Thursday, February 3, 2